The article discusses the growing shortage of physicians in the U.S., projected to be 86,000 by 2036, including 40,400 primary care physicians. Health systems are increasingly relying on Advanced Practice Providers (APPs) to fill the gap. While APPs can efficiently expand access to care, some experts argue they should complement, not replace, physicians. The debate continues on whether APP-led teams can maintain high-quality care and control costs effectively.
Author: Abhay Panchal
The FDA has expanded the approval of Voquenza to include heartburn relief for patients with nonerosive gastroesophageal reflux disease (GERD). This decision is based on clinical data demonstrating the efficacy and safety of Voquenza in alleviating heartburn symptoms in this patient population. The expanded approval offers a new treatment option for individuals suffering from nonerosive GERD, addressing a significant need in gastroenterology care.
Artificial intelligence (AI) is unlikely to replace physicians due to several factors. While AI can assist with data analysis and administrative tasks, it cannot replicate the nuanced understanding and personal connection that human doctors provide. The Medical Futurist highlights five fundamental reasons why AI won’t replace doctors – and it never will.
A recent Newsweek article reveals that nearly half of Americans find healthcare unaffordable. The rising costs are placing a significant financial burden on individuals, even those with insurance, leading many to delay or skip necessary medical care. Systemic issues such as lack of price transparency, complex billing, and inefficiencies within the healthcare system contribute to this problem, exacerbating health disparities and increasing the financial strain on families.
The U.S. News & World Report rankings for best hospitals in gastroenterology and GI surgery highlight the top medical centers excelling in these specialties. The rankings are based on various factors, including patient outcomes, expert opinions, and key metrics related to care quality and patient safety. These rankings help patients find high-quality care for complex and challenging conditions related to the digestive system.
On May 29, 2024, Gastroenterology Associates of Central Florida, P.A., known as the Center for Digestive Health, reported a data breach affecting patients’ names, Social Security numbers, and financial information. Unauthorized access occurred between April 1 and April 14, 2024. The organization has since sent out notifications to those impacted and is working with third-party security experts to investigate and secure their systems. Affected individuals are advised to consult a data breach lawyer to protect against fraud or identity theft.
The Medscape article discusses gastrointestinal (GI) side effects that prescribers of GLP-1 receptor agonists should be concerned about. These medications, often used for diabetes and weight management, can cause nausea, vomiting, diarrhea, and constipation. More serious but less common side effects include pancreatitis, gallbladder disease, and delayed gastric emptying. Prescribers should monitor patients closely for these side effects and provide appropriate management strategies.
The CMS 2025 proposed payment regulations include a 2.8% cut for physician services, which major medical organizations, including the American Society for Gastrointestinal Endoscopy (ASGE), oppose. This cut threatens GI practices and patient access to care. Other key changes involve ending COVID-19 telehealth flexibilities, maintaining current telemedicine codes, expanding colorectal cancer screening coverage, and introducing a new MIPS Value Pathway specific to gastroenterology. ASGE urges Congress to adopt changes that tie physician payments to the Medicare Economic Index.
The article features insights from Dr. Prateek Sharma on various aspects of gastroenterology, including the effectiveness of stool tests, advancements in endoscopy, the role of proton pump inhibitors (PPIs), the integration of AI in gastrointestinal procedures, and the importance of proper bowel preparation. Dr. Sharma emphasizes that technological advancements, particularly AI, have the potential to significantly enhance diagnostic accuracy and patient outcomes in gastroenterology.
A phase 3b trial compared risankizumab with ustekinumab in patients with moderate-to-severe Crohn’s disease. Patients were treated for 48 weeks after inadequate response or unacceptable side effects from anti-TNF therapy. Risankizumab was noninferior in achieving clinical remission at 24 weeks (58.6% vs. 39.5%) and superior in endoscopic remission at 48 weeks (31.8% vs. 16.2%). Both drugs had similar adverse event rates. The study was funded by AbbVie.